Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) reported an inducement grant under Nasdaq Listing Rule 5635(c)(4) consisting of 36,447 restricted stock units awarded to 12 newly hired non-executive officers with a grant date of April 16, 2026.
The RSUs vest over four years with 25% vesting on each anniversary, conditional on continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
In the Apr 27 session, RARE declined 0.46%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | BLA resubmission accepted | Positive | +4.8% | FDA acceptance of UX111 BLA resubmission with set PDUFA action date. |
| Mar 30 | IND clearance | Positive | -0.4% | FDA clears IND for UX016 enabling Phase 1/2 study in GNE myopathy. |
| Mar 27 | Class action notice | Negative | -0.4% | Notice of class action lawsuit application deadline for shareholders. |
| Mar 20 | Inducement RSU grant | Neutral | +2.0% | Disclosure of 10,839 RSUs granted to two newly hired officers. |
| Mar 12 | Phase 3 data update | Positive | -2.3% | Positive 36-week Phase 3 DTX301 data with significant ammonia reduction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed alignment: positive regulatory and clinical updates have sometimes led to gains but also to selloffs, while routine items like inducement grants and legal notices saw modest, directionally consistent moves.
Over the past two months, Ultragenyx has reported several key developments. The FDA accepted the resubmitted BLA for UX111 with a PDUFA date of September 19, 2026, and cleared an IND for UX016 with a Phase 1/2 study planned in the second half of 2026. Positive Phase 3 data for DTX301 showed meaningful ammonia reductions. Alongside this, the company issued multiple inducement RSU grants and faced a class action notice, illustrating a mix of operational progress and routine corporate/legal updates relative to today’s inducement grant.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
employment inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 36,447 restricted stock units of the company’s common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
